Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.
about
Melioidosis: epidemiology, pathophysiology, and management.Management of melioidosisA case of melioidosis presenting as migrating pulmonary infiltration: the first case in KoreaModified virulence of antibiotic-induced Burkholderia pseudomallei filaments.Does prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials.Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units)Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.Treatment and prophylaxis of melioidosisAntibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.Continuous beta-lactam infusion in critically ill patients: the clinical evidenceContinuous versus intermittent administration of piperacillin-tazobactam in intensive care unit patients with ventilator-associated pneumoniaPopulation pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admission.Antimicrobial stewardship in the intensive care unit: a focus on potential pitfalls.β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review.Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.Out of hospital treatment of patients with melioidosis using ceftazidime in 24 h elastomeric infusors, via peripherally inserted central catheters.Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?Primary melioidotic prostatic abscess: presentation, diagnosis and management.Melioidosis in systemic lupus erythematosus: the importance of early diagnosis and treatment in patients from endemic areas.Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendationContinuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?Use of cryopoor plasma for albumin replacement and continuous antimicrobial infusion for treatment of septic peritonitis in a dog.Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients
P2860
Q24522461-A722CC01-DF7E-4A7F-8489-F062FF15F5F8Q28245689-FE903AF2-5C55-47EB-BE3D-777166751C6EQ33599284-813AFEE7-AB27-4912-A8E4-75CF54E209F1Q33857445-41CCAE37-0CD6-407C-B2FA-4CA77FC4E8EDQ33940174-755EA178-1B35-4BE9-B166-6C581A3F87CFQ34111057-F5443390-C342-43AA-822A-582FDFCABD5CQ34153182-360DE0E9-A8BB-43BB-BF2F-D8592DF4A03BQ34538191-ABF35ED1-EE30-4A0F-98AB-450C7193BFF7Q35908084-B388B95A-7C0E-4EA1-AC8C-C7544B05D384Q36329228-CDEEDE8D-E23A-40E3-A5D6-E8C6FA246263Q36422575-C430555F-35EB-40DF-9542-D7C9C0154E20Q37392874-3E9FAE13-1943-42B3-B22F-F88E1E70DFDCQ37867266-CCA6E02A-4A7A-4C89-902B-34E63ECCF36FQ38004063-05DC4AA0-9453-4DE6-97E4-EBFB6F17DC17Q38896040-4465B1AF-B802-4376-8EBD-6AF7A831272CQ39085560-48D1DC61-1FA2-4155-B37F-F6CD4BA3E001Q39344408-DC851B25-1CA6-46F7-933A-68A9872F85AAQ40578680-44A3BEB6-2399-459F-85D2-94218B539EBFQ40590388-8A719BFE-3E92-4D21-9ECF-6FE5BAE0F56FQ42203839-953DE43E-3A6D-478C-A50D-8D3146F305C8Q42432137-7EB57309-F8D7-49CD-80FD-B72740E0450BQ51024819-FB09B458-6313-416C-BADB-B64F0CAF3D9FQ58701649-B205EA89-C53B-4241-8854-3E56262DEF16
P2860
Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Pharmacokinetic-pharmacodynami ...... on in septicaemic melioidosis.
@ast
Pharmacokinetic-pharmacodynami ...... on in septicaemic melioidosis.
@en
type
label
Pharmacokinetic-pharmacodynami ...... on in septicaemic melioidosis.
@ast
Pharmacokinetic-pharmacodynami ...... on in septicaemic melioidosis.
@en
prefLabel
Pharmacokinetic-pharmacodynami ...... on in septicaemic melioidosis.
@ast
Pharmacokinetic-pharmacodynami ...... on in septicaemic melioidosis.
@en
P2093
P2860
P1476
Pharmacokinetic-pharmacodynami ...... on in septicaemic melioidosis.
@en
P2093
V Wuthiekanun
W Chaowagul
Y Suputtamongkol
P2860
P304
P356
10.1111/J.1365-2125.2000.00179.X
P407
P577
2000-08-01T00:00:00Z